echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > With the intensification of involution, where is the breakthrough for local pharmaceutical companies to "go overseas"?

    With the intensification of involution, where is the breakthrough for local pharmaceutical companies to "go overseas"?

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Market Analysis] In recent years, with the rising cost of new drug research and development and the intensification of the domestic pharmaceutical market, the overseas track has gradually entered the field of vision of domestic investo.
    Recently, KPMG and GBI jointly released the "White Paper on Chinese Pharmaceutical Companies Going Overseas", which pointed out that in 2020, China's innovative drugs will enter the outbreak period of "going oversea.
    A total of 271 cases have been recorded, achieving an increase of 300% in five yea.
    For local pharmaceutical companies, turning their attention to overseas markets is undoubtedly a new way out, but the process of “going overseas” is not as simple as imagin.
    From some cases of “going overseas” failures, it can be seen that there are many challenges in overseas markets, and pharmaceutical companies are faced with the goal of A series of issues such as national market registration supervision, business and competition, access, investment and tax environme.
    Judging from the direction chosen by local pharmaceutical companies to go overseas, the European and American markets are mostly the first stop, which is mainly related to factors such as the high global consensus on the FAD standard, the strong market share of the US market and the relatively free pricing power of innovative dru.
    In recent years, there have been many cases where local pharmaceutical companies have applied to the FAD for their produc.
    For example, at the end of February this year, Legend Bio's CAR-T therapy Sidaki Aurexa was successfully approved by the FDA for the treatment of relapsed/refractory multiple Myeloma (r/r MM) patients, this is also the second innovative drug successfully launched in the United States after BeiGene's zanubrutin.
    It is worth mentioning that the FAD threshold is relatively high and the review system is stri.
    Although local pharmaceutical companies have a strong desire to sprint FAD, the actual number of approvals is very limit.
    Many pharmaceutical companies include Wanchun, Innovent, and Huang Medicine and others have all failed to break throu.
    The industry believes that in addition to the mature markets in Europe and the United States, local pharmaceutical companies can also synthesize their own competitive advantages to find new breakthroughs, such as targeting emerging market countri.
    In recent years, the state has successively introduced policies to encourage and support innovative pharmaceutical companies to "go overseas" to emerging market countri.
    Emerging markets have untapped and unincorporated market space and potential, while Chinese innovative drugs are generally cost-effective and more suitable for developing countri.
    patient nee.
    It is understood that many local pharmaceutical companies have turned their targets to emerging market countri.
    For example, on June 14, Innovent Bio's innovative drug Dayoutong was approved for marketing in Indonesia for the treatment of metastatic colorectal cancer, ovarian cancer, cervical cancer and other high-incidence tumo.

    On June 14, the clinical and commercial cooperation between Kintor and Etana in Indonesia was successfully selected as the “One Belt, One Road” innovation cooperation project as the project of “Clinical Trial Cooperative R&D and Overseas Application Demonstration of Anti-COVID-19 Drug.

    Kintor Pharmaceutical stated that the successful establishment of the project marks the recognition of the company's R&D capabilities and innovation cooperati.

    On June 13, Henlius announced that it had signed a license and supply agreement with Organon, a subsidiary of Merck & .

    , which granted the latter two products except China's Pertuzumab biosimilar HLX11 and denosumab biosimilar HLX1 Exclusive commercialization rights worldwide, including many emerging marke.

    Henlius will receive $541 million in potential revenue from .

    In addition, BeiGene also stated that zanubrutinib has been approved in 50 markets around the world, including many breakthroughs in emerging marke.

    It has been approved in Kuwait, Bahrain and Qatar, and continues to expand in the Middle East and North Afri.

    However, although the emerging market space is broad enough, different regions have different characteristi.

    Local pharmaceutical companies going overseas to emerging market countries may face challenges such as unformed market rules and imperfect pharmaceutical foundatio.

    Moving to commercial production continues to explo.
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.